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 Background: Subclinical graft inflammation and fibrosis after pediatric liver transplantation (LT) are common. Biomarkers 
are needed that precede and are associated with these changes and graft outcome.
 Material/Methods: We evaluated immunohistochemical expression of 6 biomarkers [a-smooth muscle actin (a-SMA), collagen I, 
decorin, vimentin, P-selectin glycoprotein ligand-1 (PSGL-1), and CD34] in biopsies taken intraoperatively at LT 
(baseline) (n=29) and at 11.3 years after LT (first follow-up) (n=51). Liver biochemistry and graft histology were 
assessed at the first follow-up and at final assessment (19.6 years after LT) (n=48). Second follow-up biopsies 
for histology were available from 24 patients. The immunostainings were correlated with liver histology, bio-
chemistry, and outcome at these time-points.
 Results: Baseline levels of the biomarkers were unrelated to presence of fibrosis at follow-up. Increased a-SMA, collagen 
I levels, decorin, and vimentin were associated with simultaneous fibrosis at the first follow-up (p=0.001–0.027). 
Increased SMA, collagen I, decorin, vimentin, PSGL-1, and CD34 expression at first follow-up were associated with 
simultaneous portal inflammation (p=0.001-0.025). a-SMA, decorin, and vimentin expression were increased in 
patients without fibrosis at the first follow-up but who developed fibrosis in second follow-up (p=0.014 p=0.024 
and p=0.024). Significant fibrosis (F2) and markedly increased a-SMA, collagen I, decorin, and vimentin levels 
at first follow-up were associated with suboptimal liver status at the final assessment (p=0.002–0.042).
 Conclusions: The expression of the biomarkers at LT was unrelated to later development of graft fibrosis. a-SMA, decorin, 
and vimentin were associated with later graft fibrosis and suboptimal liver status.
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Background
Liver transplantation (LT) is a curative treatment for chronic 
and acute liver failure in children and adults. The long-term 
outcome of LT patients has improved during recent decades, 
with a 20-year survival currently over 80% [1]. However, seri-
al liver biopsies have demonstrated a gradual development 
of graft inflammation, fibrosis, steatosis, and bile duct loss 
in clinically stable pediatric patients with nearly normal liver 
biochemistry [2–5]. The mechanism and significance of these 
histopathological changes remain unclear.
Thus far, few studies have evaluated the cellular and molec-
ular mechanisms of chronic fibrosis and inflammation in liver 
grafts [6–11]. In this study, we focussed on 6 immunohisto-
chemical biomarkers that cover different aspects of liver pa-
thology. a-smooth muscle cell actin (a-SMA) is a widely used 
marker for activated hepatic stellate cells (HSCs), which are re-
sponsible for the over-production of extracellular matrix (ECM) 
components and development of fibrosis [12,13]. Type I colla-
gen is a marker of ECM accumulation and fibrosis [14]. Decorin 
is an ECM protein and a natural inhibitor of the main pro-fi-
brotic cytokine, transforming growth factor-b1 [15]. Vimentin 
is expressed in activated HSCs, Kupffer cells, and endotheli-
um and it is used as a marker of epithelial-to-mesenchymal 
transition [16–18]. P-selectin glycoprotein ligand 1 (PSGL-1) is 
an adhesion molecule expressed on several types of immune 
cells [19]. It has a major role in trafficking of inflammatory cells 
into liver sinusoids, which is an essential part of liver injury 
and fibrosis [20]. Finally, CD34 is an endothelial cell marker 
for increased neovascularization and capillarization that com-
monly occurs in liver injury and fibrosis [21–24].
In addition to conventional histological evaluation, immuno-
histochemical biomarker studies can reveal early changes at 
the molecular level and help to interpret histological findings. 
Previous studies have reported that increased a-SMA and vi-
mentin expression measured during the first year after LT can 
precede development of graft fibrosis [6–11]. It has been hy-
pothesized that a-SMA expression of the graft at the time of 
LT is associated with the development of fibrosis [8].
The aim of this study was to investigate the immunohisto-
chemical expression of a-SMA, type I collagen, decorin, vimen-
tin, PSGL-1, and CD34 as related to graft histopathology, liv-
er biochemistry, and long-term outcome. We investigated the 
biomarker expression from liver biopsies taken at the time 
of surgery and at a median follow-up of 11.3 years after LT. 
The results were correlated with graft histology and biochem-
istry, as well as with the clinical liver status at a median time 
of 19.6 years after LT.
Material and Methods
Patients
Between 1987 and 2007, 99 pediatric patients (age <18) un-
derwent deceased donor LT in Finland. All operations and most 
of the follow-up occurred at the Helsinki University Hospital. 
Data on these patients were gathered in 2009-2011, referred to 
here as the first follow-up, a median of 11.3 (range, 2.8–22.3) 
years after LT. At that time, 33 patients had died, 10 did not 
give consent to participate in the study, 3 had insufficient liver 
biopsy samples for analyses, and 2 patients underwent re-LT 
at that time. All 51 patients (77% of the 66 survivors) includ-
ed in this study underwent percutaneous liver biopsy sampling 
for histology and immunohistochemistry and had blood bio-
chemistry measurements. All patients displayed nearly stable 
graft function (Table 1).
In 29 of the 51 study patients, a liver graft biopsy sample tak-
en at the time of surgery, referred to here as baseline, was 
available for immunohistochemical stainings.
Clinical and blood biochemistry data were gathered from 48 pa-
tients (3 patients were deceased due to causes unrelated to LT) 
at the final assessment (latest patient visit before November 
2019), which occurred a median of 8.3 (range, 4.7–10.3) years 
after the first follow-up and 19.6 (range, 10.17–28.44) years after 
LT. Second follow-up liver biopsies, taken after the first follow-up 
but before October 2017, were available from 24 patients for his-
tological evaluation. These biopsies were taken a median of 4.5 
years (range, 1.1–7.3) after the first follow-up and a median of 
18.9 (range, 4.8–25.4) years after the LT. Sixteen (67%) of these 
biopsies were taken as protocol biopsies from asymptomatic 
patients and 8 were taken due to suspicion of acute rejection.
Study design
The timeline of the study can be seen in Figure 1. The baseline 
biomarker levels were correlated with the histological findings 
at the first follow-up. Immunohistochemical findings at the first 
follow-up were correlated with simultaneous graft histology 
and liver biochemistry. The predictive value of the biomarkers 
was analyzed by comparing the immunohistochemical findings 
at the first follow-up with histological findings of the second 
biopsy and liver status at the final assessment.
Liver graft biopsies
The first and second follow-up biopsies were percutaneous core 
needle biopsies of the liver grafts, which were taken by expe-
rienced radiologists under ultrasound guidance. Intraoperative 
samples at LT were surgical wedge biopsies taken before re-
moval of the liver graft.
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Immunohistochemical	analyses
Immunohistochemical stainings on formalin-fixed samples 
were performed as previously reported [25]. The antibodies 
used were as follows: 1) Collagen type 1 monoclonal antibody 
clone 1-8AH5 (1: 1000) (Abnova Corporation); 2) a-SMA, CD34 
and vimentin antibody clones 1A4 (1: 200), QBEn10 (1: 100) 
and 3B4 (1: 100) (Dako Aligent Technologies), respectively; 
3) Decorin polyclonal rabbit antibody clone NBP1-84970 (1: 750) 
(Novus Biologicals); and 4) PSGL-1 monoclonal antibody clone 
sc-13535 (1: 500) (Santa Cruz Biotechnology).
Immunohistochemical stainings were graded semiquantitative-
ly without knowledge of the patients’ clinical stage. The scor-
ing was performed according to a previously validated scor-
ing system introduced by Chevallier et al. that was modified 
to correspond to the observed immunohistochemical staining 
patterns [26]. The staining patterns of the biomarkers at the 
portal areas are presented in Figure 2.
a-SMA, type I collagen, and decorin expression in portal ar-
eas were evaluated on a scale from 0 to 2 (0=mild staining re-
stricted to portal area, 1=extended periportal staining without 
bridging, 2=periportal staining with bridging). Lobular expres-
sion was evaluated based on the staining of sinusoidal walls 
or EMC (0=absent or slight staining, 1=continuous staining, 
2=intense staining). Evaluation of central areas was based on 
the rim around the central vein (0=none or slight rim, 1=con-
tinuous or thick rim, 2=pericentral staining). Portal, lobular, 
and central scores were added for an overall score of 0 to 6.
PSGL-1 and vimentin staining of portal areas were evaluated 
on a scale of 0 to 2 (0=absent or slight, 1=increased, 2=ex-
tended). In lobular areas, scoring was based on the number 
of positive cells at sinusoids (0=none or a few positive cells, 
1=increased number of positive cells, 2=markedly increased 
number of positive cells). Central expression of PSGL-1 and vi-
mentin were scored in a similar fashion to a-SMA, type I col-
lagen, and decorin.
CD34 scoring was based on the number of CD34-positive sinu-
soids in portal (0=normal, 1=increased, 2=markedly increased) 
and central areas (0=absent, 1=some CD34 positive sinusoids, 
2=several CD34 positive sinusoids).
Graft histology
Graft histology was evaluated from the first and second fol-
low-up liver biopsies stained with hematoxylin and eosin and 
Masson’s trichrome. First and second follow-up biopsies con-
tained a median of 10 (7–16) and 14 (11–19) portal areas, re-
spectively. Two pathologists with expertise in liver histopa-
thology evaluated the histological findings unaware of the 
patients’ clinical status. Inflammation was graded according 
to the Banff criteria (grades from 0 to 3) and portal fibrosis 
was staged according to the Metavir staging, from mild fibro-
sis (F0) to cirrhosis (F4) [27,28]. Sinusoidal and central fibro-
sis was scored as absent or present.
Table 1.  Patient characteristics of all patients (n=51). Data 
presented as number of patients (percentage) for 
non-continuous variables and as median (IQR) for 
continuous parameters.
All patients (n=51)
Sex n (Male/Female) 23/28
Diagnosis of liver disease
Biliary atresia n (%)  19 (34)
Metabolic disease* n (%)  8 (16)
Hepatitis n(%)  7 (14)
Hepatic malignancy n (%)  5 (10)
PKD/congenital fibrosis n (%)  4 (8)
Other** n (%)  8 (14)
Surgical characteristics
Age at LT (years)  3.3 (1.3–13.6)
Time from LT to first  
follow-up (years)
 11.3 (4.1–18.0)
Age at first follow-up (years)  18.2 (10.9–23.2)
Biochemistry at the first follow-up
ALT (U/L)  21 (14–32)
GT (U/L)  17 (13–34)
Total bilirubin (µmol/L)  10 (8–14)
Prealbumin (mg/L)  210 (170–238)
Platelets (E9/L)  216 (171–282)
Time from first follow-up to 
follow-up (years)
 8.4 (7.4–9.3)
Age at follow-up (years)  25.7 (19.4–32.3)
ALT – alanine transaminase; AP – alkaline phosphatase; 
GT – g-glutamyl transferase; IQR – interquartile range; 
LT – liver transplantation; PKD – polycystic kidney 
disease; * Diagnostic group metabolic included: Familial 
hypercholesterolemia (1), hyperoxaluria (1), morbus Wilson (1), 
OTC-deficiency (1), and tyrosinemia (4). ** Diagnostic group 
others included: Budd-Chiari syndrome (1), HUS (1), extrahepatic 
portal vein thrombosis (1), liver failure of unknown etiology (1), 
MIRAS mitochondrial recessive ataxia syndrome (1), iron 
poisoning (2), and sclerosing cholangitis (1).
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Figure 1.  Study timeline. The biomarker immunostainings were performed on 29 biopsies taken intraoperatively at the LT (baseline 
biopsies). At the first follow-up a median of 11.3 years after LT, the biomarker expression, liver biochemistry, and histology 
were assessed in 51 patients. Liver biochemistry and clinical status of the liver were recorded at the final assessment at a 
median of 8.4 years after the first follow-up and 19.6 years after LT. Second liver biopsies taken after the first follow-up but 
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Clinical follow-up
Blood tests for alanine aminotransferase (ALT), g-glutamyl trans-
ferase (GT), total bilirubin, prealbumin, and platelet count were 
performed in the first follow-up and at the final assessment. 
At the final assessment, liver status was considered subopti-
mal in case of a re-transplantation, diagnosis of chronic rejec-
tion, or in case of 1 or more of the following laboratory find-
ings: total bilirubin level over 25 µmol/L, GT over 50 U/L, ALT 
over 60 U/L, or thromboplastin time (TT) under 70%.
Statistical analysis
Statistical analyses were performed with SPSS 25.0 statistics 
software (IBM, Somers, NY). Data are presented as frequencies 
and percentages or as medians with interquartile range (IQR) 
or with range. To compare differences between groups, the 
Mann-Whitney U test was used for continuous variables and 
the Kruskal-Wallis test was used for ordinal variables. Fisher’s 
exact test was used to evaluate the significance of dependency 
between dichotomous variables. Correlations were calculated 
with the Spearman rho two-tailed test. Differences between 2 
ordinal dependent variables (change in biomarkers expression) 
were calculated with the Wilcoxon signed rank test.
Only two-sided p-values were used. Two-sided p-values <0.05 
were considered statistically significant.
Ethics
The study protocol adhered to the ethical principles of the 
1975 Declaration of Helsinki. This study was approved by the 
Ethics Committee of Children’s Hospital, Helsinki and Uusimaa 
Hospital District (IRB approval number 345/13/03/03/2008). 
All participating patients (and in case of minors, also their par-
ents) signed an informed consent form.
Figure 2.  Portal a-SMA expression grades 0, 1, and 2 (A–C). Portal type I collagen expression grades 0, 1, and 2 (D–F). Portal vimentin 
expression grades 0, 1, and 2 (G–I). Portal decorin expression grades 0, 1, and 2 (J–L). Portal PSGL-1 expression grades 0, 1 
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Results
Biomarker expression pattern
The biomarker expression at the baseline (n=29) and at the 
first follow-up biopsies without fibrosis (n=51) was mostly 
weak (score 0). At baseline, frequencies of increased staining 
(score >1) in the portal, lobular, and central areas were as fol-
lows: a-SMA 15–32%; type I collagen 7–22%; decorin 6–17%; 
vimentin 0–32%; PSGL-10-33%; and CD34 16–32%. The im-
munohistochemical findings at the first follow-up are pre-
sented in Table 2. The expression of the biomarkers showed 
no significant changes from the baseline to the first follow-
up (Wilcoxon rank test p-values ranging from 0.096 to 1.00).
Of the 29 patients with follow-up biopsy, 15 had neither fi-
brosis nor inflammation; instead, 14 had fibrosis or inflam-
mation or both at the first follow-up biopsy. Increased bio-
marker expression at baseline was not associated with these 
histopathological findings of the first follow-up (Fisher’s exact 
test p-values ranging from 0.065 to 1.00). In addition, we in-
vestigated the association of baseline expression of the bio-
markers with the presence of fibrosis and inflammation sep-
arately (see below).
Biomarkers and graft fibrosis
At the first follow-up, a median of 11.3 years after LT, 39% 
(20/51) of the liver specimens showed portal fibrosis, which 
was mild (F1) in 14/20, moderate (F2) in 4/20, and severe (F3) 
in 2/20 samples. Sinusoidal and central fibrosis were present 
in 4 (8%) and 7 (14%) biopsies, respectively. In fibrotic grafts, 
the levels of a-SMA and type I collagen were clearly increased 
in all 3 histological areas (portal, lobular, and central) (Table 2). 
Decorin expression was increased in lobular areas, and vimen-
tin was increased in portal and lobular areas (Table 2). PSGL-
1 and CD34 expressions were unrelated to the presence of fi-
brosis. The combined scores (of the 3 areas) of a-SMA, type I 
collagen, decorin, and vimentin were correlated with the con-
current fibrosis stage (Figure 3A–3D). The combined scores of 
PSGL-1 and CD34 levels showed no correlation with fibrosis 
stage (Figure 3E, 3F).
Of the 29 patients with baseline biopsy, 19 (66%) had no fi-
brosis (F0) at the first follow-up, 9 (31%) had mild fibrosis 
(F1), and only 1 (3%) had severe fibrosis (F3). Baseline expres-
sion of the biomarkers was unrelated to the presence of fi-
brosis at the first follow-up (Fishers exact test p-values rang-
ing from 0.053 to 1.00).
Second follow-up biopsies were available from 24 out of 51 
patients. Biopsies were taken at a median of 4.5 years after 
the first follow-up. To evaluate the ability of the biomarkers 
to predict development of fibrosis, we included only those pa-
tients without fibrosis (F0) at the first follow-up. Of the 24 pa-
tients with second follow-up biopsy, 15 had no fibrosis (F0) in 
the first follow-up biopsy. At the second follow-up, 11 of them 
still had no fibrosis and 4 had developed fibrosis. The portal 
expression of a-SMA, decorin, and vimentin was increased in 
these F0 biopsies of first follow-up in patients who developed 
fibrosis between these 2 time-points compared to those who 
did not (Figure 4). The expression of the other biomarkers was 
not associated with the development of fibrosis (Fischer’s ex-
act test p-values ranging from 0.154 to 1.00).
Biomarkers and graft inflammation
At the first follow-up, portal inflammation was present in 25% 
(13/51) of the biopsy samples and it was mostly mild (12/13). 
Portal inflammation was weakly correlated with portal fibrosis 
(r=0.315, p=0.024). The portal expression of a-SMA, type I col-
lagen, decorin, vimentin, and PSGL-1 were increased in grafts 
with portal inflammation (Table 3). Increased CD34 staining 
was observed in central areas with inflammation (Table 3). 
The grade of portal inflammation was correlated with the com-
bined scores (of the 3 areas) of all biomarkers: a-SMA, type I 
collagen, decorin, vimentin, PSGL-1, and CD34 (a-SMA r=0.433, 
p=0.003; type I collagen r=0.326, p=0.025; decorin r=0.318, 
p=0.048; vimentin r=0.399, p=0.010; PSGL-1 r=0.463, p=0.005 
and CD34 r=0.445, p=0.002).
Of the 29 patients with baseline biopsy, 24 (83%) had no in-
flammation at the first follow-up and 5 (17%) had mild in-
flammation (Grade 1). Increased baseline expression of portal 
PSGL-1 was related to the presence of portal inflammation at 
the first follow-up, as all patients who had increased (³1) por-
tal expression of PSGL-1 at baseline had inflammation at the 
first follow-up (n=2), and of the 17 patients who had normal 
(0) portal PSGL-1 expression at baseline, 16 had no inflamma-
tion at the first follow-up (Fisher’s exact test p=0.018). Other 
biomarkers showed no association with the presence of por-
tal inflammation in the first follow-up biopsies (Fisher’s exact 
test p-values ranging from 0.298 to 1.00).
Periportal, lobular, bile duct, or endothelial inflammation and 
bile duct loss were so rare (3/51, 3/51, 0/51, 0/51, and 3/51, 
respectively) that the associations of the 6 biomarkers were 
not tested.
Biomarkers and concurrent graft function
The 51 patients at the first follow-up had normal or nearly 
normal plasma levels of ALT, GGT, total bilirubin, prealbumin, 
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Table 2.  Biomarker scores of the liver graft biopsies obtained at the first follow-up in the whole group (n=51) and in those with (n=20) 
and without (n=31) simultaneous fibrosis. Data are presented as number of patients in each group (percentage). Some of the 
biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 3 histological areas. For this reason, the number 















0 29 (63) 24 (86) 5 (28)
1 12 (26) 4 (13) 8 (44)
2 5 (11) 0 (0) 5 (28)
Lobular 0.000
0 25 (54) 21 (68) 4 (22)
1 10 (22) 6 (19) 4 (22)
2 11 (24) 1 (3) 10 (56)
Central 0.027
0 36 (78) 25 (89) 11 (61)
1 7 (15) 2 (7) 5 (28)
2 3 (7) 1 (4) 2 (11)
Type I collagen 
Portal 0.001
0 31 (63) 24 (80) 7 (37)
1 13 (27) 6 (20) 7 (37)
2 5 (10) 0 (0) 5 (26)
Lobular 0.006
0 41 (82) 29 (94) 12 (63)
1 7 (14) 2 (7) 5 (26)
2 2 (4) 0 (0) 2 (11)
Central 0.002
0 38 (79) 28 (93) 10 (56)
1 7 (15) 2 (7) 5 (28)















0 26 (63) 17 (71) 9 (53)
1 11 (27) 7 (29) 4 (24)
2 4 (10) 0 (0) 4 (24)
Lobular 0.010
0 28 (68) 20 (83) 8 (47)
1 10 (24) 4 (17) 6 (35)
2 3 (7) 0 (0) 3 (18)
Central 0.055
0 33 (83) 22 (92) 11 (69)
1 5 (13) 2 (8) 3 (19)
2 2 (5) 0 (0) 2 (13)
Vimentin
Portal 0.001
0 17 (42) 15 (63) 2 (12)
1 18 (44) 8 (33) 10 (59)
2 6 (12) 1 (4) 5 (29)
Lobular 0.010
0 23 (56) 17 (71) 6 (35)
1 14 (34) 7 (29) 7 (41)
2 4 (10) 0 (0) 4 (24)
Central 0.769
0 38 (93) 22 (92) 16 (94)
1 0 (0) 0 (0) 0 (0)
2 3 (7) 2 (8) 1 (6)
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Table 2. continued  Biomarker scores of the liver graft biopsies obtained at the first follow-up in the whole group (n=51) and in 
those with (n=20) and without (n=31) simultaneous fibrosis. Data are presented as number of patients in each 
group (percentage). Some of the biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 
















0 21 (57) 14 (67) 7 (44)
1 11 (30) 5 (24) 6 (38)
2 5 (14) 2 (10) 3 (19)
Lobular 0.366
0 32 (87) 19 (91) 13 (81)
1 3 (8) 2 (10) 1 (6)
2 2 (5) 0 (0) 2 (13)
Central 0.252
0 36 (97) 21 (100) 15 (94)
1 0 (0) 0 (0) 0 (0)















0 38 (80) 23 (79) 15 (79)
1 9 (19) 5 (17) 4 (21)
2 1 (2) 1 (3) 0 (0)
Central 0.280 
0 33 (69) 22 (76) 11 (58)
1 13 (27) 5 (17) 8 (42)
2 2 (4) 2 (7) 0 (0)
a-SMA – a-smooth muscle actin; PSGL-1 – P-selectin 
glycoprotein ligand-1. * p-value for the significance of the 
difference in the distribution of biomarker scores between 
patients without and with fibrosis calculated with Kruskal-Wallis 
test.
and platelets (Table 1). Patients with increased expression (³1 
at any of the 3 histological areas) of a-SMA, type I collagen, 
decorin, and vimentin showed slightly lower prealbumin lev-
els than patients with normal stainings [188 (167–219) mg/L 
vs. 234 (205–269) mg/L p=0.001, 184 (168–218) mg/L vs. 
244 (201–268) mg/L p=0.012, 178 (164–222) mg/L vs. 222 
(197–258) mg/L p=0.020 and 186 (165–222) mg/L vs. 234 
(212–268) mg/L p=0.003, respectively]. Also, patients with fi-
brosis showed lower prealbumin compared to those without 
fibrosis, but values were in the nearly normal range [189 (163–
224) mg/L vs. 219 (184–267) mg/L p=0.036]. Patients with in-
flammation showed higher total bilirubin levels compared to 
those without inflammation, but values were in the normal 
range [12 (10–18) µmol/L vs. 9 (7–13) µmol/L p=0.033].
Biomarkers and graft outcome
At the final assessment at a median of 8.3 years after the first 
follow-up and a median of 19.6 years after LT, the liver status 
was evaluated from all 48 patients (3 patients had died due 
to causes unrelated to LT). The liver status was suboptimal in 
12 patients: 2 had been re-transplanted, 1 patient had severe 
chronic rejection, and 9 patients had abnormalities in liver 
biochemistry. Three-quarters of the patients had completely 
normal findings (36/48). Moderately increased (³1) biomark-
er levels at the first follow-up were not predictive of the liver 
status at the final assessment. Presence of significant fibro-
sis (F³2) and markedly increased (³2) scores of portal a-SMA, 
type I collagen, decorin, and vimentin and lobular expressions 
of decorin and vimentin at the first follow-up were associated 
with suboptimal liver status at the final assessment (Table 4). 
Presence of portal inflammation at the first follow-up was not 
associated with later liver status (Table 4).
Discussion
We analyzed the expression of 6 immunohistochemical biomark-
ers in liver grafts from pediatric LT patients and correlated the 
staining patterns and intensities with simultaneous and follow-
up liver graft histopathology, biochemistry, and clinical outcome. 
Biomarker expression in graft biopsies taken perioperatively was 
not associated with later graft fibrosis. At follow-up, portal, lobu-
lar, and central a-SMA, and collagen I, lobular decorin, and portal 
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and lobular vimentin were increased in liver grafts with fibro-
sis. Inflammation was associated with increased portal stain-
ing of a-SMA, collagen I, decorin, vimentin, PSGL-1, and central 
CD34. The expression of the biomarkers showed little correla-
tion with liver biochemistry. Portal a-SMA, decorin, and vimen-
tin expression was increased in patients who had no fibrosis 
at first follow-up but who developed fibrosis in second follow-
up. Significant fibrosis (F2) and markedly increased a-SMA, col-
lagen I, decorin, and vimentin levels at first follow-up were as-































































































































Figure 3.  Combined (portal, lobular, and central) biomarker expression scores (columns) in different stages of fibrosis according 
to Metavir at the first follow-up (X-axis). The Y-axis presents the percentage of all patients. Correlation between 
immunohistochemistry grades and stage of fibrosis calculated with Spearman’s correlation, 2-tailed p-value. a-SMA 
expression (A), type I collagen (B), vimentin expression (C), decorin expression (D), PSGL-1 expression (E), and CD34 
expression (F).
Serial liver biopsies after pediatric LT from several centers have 
demonstrated gradual development of unexplained graft in-
flammation and fibrosis [2–5]. The histological changes seem 
to proceed slowly while the patients are clinically stable and 
liver biochemistry remains nearly normal. It is clear that more 
understanding of the liver allograft injury is needed. We found 
that the biomarker expression of the 6 fibrogenic biomarkers 
was moderate in grafts with little histologically-evident fibro-
sis. The comparison of the baseline and follow-up biopsies (at 
a median of 11.3 years after LT) in the same patients revealed 
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quite similar staining patterns, indicating that the process is 
also slow at the molecular level.
The expression of a-SMA in liver diseases and grafts has 
been studied in a few reports. a-SMA is a marker of activat-
ed HSCs [12,13]. Normally, a-SMA is moderately expressed in 
portal, sinusoidal, and perivenular areas but increased a-SMA 
staining is reported in a variety of liver diseases [29]. a-SMA 
expression measured during the first years after LT seems to 
precede development of later fibrosis, but controversy exist 
on how well a-SMA staining correlates with concurrent fibro-
sis after LT [7–11,30]. In a study of 18 pediatric LT recipients, 
increased a-SMA expression predicted development of fibrosis 
during 2-year follow-up [7]. A study of 54 pediatric LT recipients 
showed that stronger a-SMA expression at 6 months was as-
sociated with present, 3-year, and 7-year fibrosis [8]. Increased 
a-SMA staining intensity at 6 months and 3 years was an in-
dependent risk factor for development of fibrosis at 7 years.
In this study, a-SMA expression was strongly correlated with 
the simultaneous stage of fibrosis and portal inflammation. 
The baseline expression of a-SMA was not associated with 
the histological findings a decade later. We found that the in-
creased portal a-SMA expression of F0 biopsies after LT was 
associated with later development of fibrosis. This is in agree-
ment with earlier findings of Gawrieh et al., who reported that 
early a-SMA expression at portal areas is associated with rapid 
development of fibrosis after LT [9]. a-SMA expression showed 
a weak correlation with serum prealbumin levels but not with 
other liver function values at the first follow-up. Increased por-
tal a-SMA staining was also associated with abnormal clinical 
findings at the final assessment 8 years later.
Type I collagen is the main ECM component in fibrotic liver le-
sions [14]. Little is known about type I collagen expression in 
liver transplants. Abundant deposition of type I collagen at the 
time of Kasai procedure was associated with worse progno-
sis in pediatric biliary atresia patients [31]. In our study, type I 
collagen expression was associated with simultaneous fibro-
sis stage in liver transplants, as expected, but showed only 
a weak correlation with later abnormal liver status and was 
no better than conventional Metavir staging in that respect.
Absent Present
p=0.014
























































Figure 4.  The expression portal a-SMA (A), decorin (B), and vimentin (C) in F0 biopsies at the first follow-up. X-axis presents the 
patients who still had no fibrosis (Absent) and who developed fibrosis (Present) during the follow-up (X-axis). The Y-axis 
presents the number of patients. P-value for the significance for dependency between portal a-SMA, decorin and vimentin 
expression at the first follow-up and presence fibrosis in the second follow-up biopsy calculated Fisher’s exact test.
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Table 3.  Biomarker scores of the liver graft biopsies obtained at the first follow-up, patients divided in those with (n=13) and without 
(n=38) simultaneous inflammation. Data are presented as number of patients in each group (percentage). Some of the 
biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 3 histological areas. For this reason, the number 











0 26 (77) 3 (25)
1 7 (21) 5 (42)
2 1 (3) 4 (33)
Lobular 0.121
0 21 (62) 4 (33)
1 6 (18) 4 (33)
2 7 (21) 4 (33)
Central 0.030
0 29 (85) 7 (58)
1 5 (15) 2 (17)
2 0 (0) 3 (25)
Type I collagen 
Portal 0.025
0 26 (68) 5 (42)
1 10 (26) 3 (25)
2 1 (3) 4 (33)
Lobular 0.551
0 31 (84) 10 (77)
1 5 (14) 2 (15)
2 1 (3) 1 (8)
Central 0.251
0 29 (83) 9 (69)
1 5 (13) 2 (15)











0 23 (74) 3 (30)
1 7 (23) 4 (40)
2 1 (3) 3 (30)
Lobular 0.372
0 22 (71) 6 (60)
1 8 (26) 2 (20)
2 1 (3) 2 (20)
Central 0.759
0 25 (83) 8 (80)
1 4 (13) 1 (10)
2 1 (3) 1 (10)
Vimentin
Portal 0.014
0 15 (52) 2 (17)
1 12 (41) 6 (50)
2 2 (7) 4 (33)
Lobular 0.116
0 18 (62) 5 (42)
1 10 (35) 4 (33)
2 1 (3) 3 (25)
Central 0.114
0 28 (97) 10 (83)
1 0 (0) 0 (0)
2 1 (3) 2 (17)
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Table 3. continued  Biomarker scores of the liver graft biopsies obtained at the first follow-up, patients divided in those with (n=13) 
and without (n=38) simultaneous inflammation. Data are presented as number of patients in each group 
(percentage). Some of the biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 3 
histological areas. For this reason, the number of scored samples shows some variation between the different 
stainings.
a-SMA – a-smooth muscle actin; PSGL-1 – P-selectin 
glycoprotein ligand-1. * p-value for the significance of the 
difference in the distribution of biomarker scores between 












0 18 (67) 3 (30)
1 8 (30) 3 (30)
2 1 (4) 4 (40)
Lobular 0.061
0 25 (93) 7 (70)
1 2 (7) 1 (10)
2 0 (0) 2 (20)
Central 0.100
0 27 (100) 9 (90)
1 0 (0) 0 (0)











0 31 (86) 7 (58)
1 4 (11) 5 (42)
2 1 (3) 0 (0)
Central 0.007
0 28 (80) 5 (39)
1 6 (17) 7 (54)
2 1 (3) 1 (8)
Decorin is an ECM protein with anti-fibrotic properties due to 
its negative impact on TGF-b1 [15,32]. In the liver, decorin is 
expressed as extracellular spot-like depositions around peri-
portal tissue, central veins, and sinusoids. Increased decorin 
expression has been demonstrated in chronic hepatitis-asso-
ciated fibrosis [33]. We found that the expression of lobular 
decorin in liver grafts was correlated with the concurrent fi-
brosis and inflammation at the first follow-up. Although base-
line expression of decorin was unrelated to later fibrosis, the 
increased portal expression of decorin in F0 biopsies taken af-
ter LT was associated with development of fibrosis.
Vimentin serves as a marker for Kupffer cells, endothelial cells, 
and HSCs, and in epithelial- and endothelial-to-mesenchymal 
transition [16–18]. In addition to its main role as a part of the 
normal cell cytoskeleton of mesenchymal cells, it may also func-
tion in fibrogenesis and in graft rejections [34,35]. In a study 
of LT recipients with hepatitis C, rapid fibrosers (Metavir F3 or 
F4 at £2 years after LT) showed clearly increased vimentin ex-
pression in F0 biopsies measured during the first year after LT 
as compared to slow fibrosers (Metavir F0 or F1 at ³2-year bi-
opsy) [6]. In our study, vimentin expression was significantly 
increased in grafts with fibrosis or inflammation. Increased 
portal expression of vimentin in F0 biopsies taken after LT 
also was associated with later development of fibrosis. This 
is especially interesting because the development anti-vimen-
tin antibodies in organ transplant patients has been associat-
ed with the development of antibody-mediated rejection [35].
PSGL-1 is involved in immune cell trafficking and regulating 
immune responses [36]. Blockade of PSGL-1 is hypothesized 
to prevent liver graft injury by inhibiting leukocyte infiltra-
tion [37,38]. In the present study, portal PSGL-1 expression 
was associated with concurrent subclinical portal inflamma-
tion after LT. We also found that increased portal expression 
of PSGL-1 at baseline (intraoperative biopsies) was related to 
subclinical inflammation at the first follow-up.
CD34 is an endothelial cell marker of neovascularization, fre-
quently seen in liver fibrosis and inflammation [21–24]. In the 
normal liver, CD34 staining can be seen in sinusoidal endothelial 
cells at the periportal area, with perivenular areas being most-
ly negative [39]. Chronic liver diseases strongly increase the si-
nusoidal staining, especially around central veins [40,41]. We 
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Table 4.  Association of any fibrosis (³1) significant fibrosis (³2), portal inflammation, and markedly increased (³2) biomarker levels at 
first follow-up with liver status (normal in 36 and suboptimal in 12) at the final assessment. Data are presented as number of 
patients and percent across rows. Some of the biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 3 

















Absent 29 7 0.143
Present 7 5
a-SMA 
portal 0–1 32 7 0.003
³2 0 4
lobular 0–1 26 7 0.248
³2 6 4
central 0–1 31 10 0.451
³2 1 1
Type I collagen
portal 0–1 34 8 0.003
³2 0 4
lobular 0–1 34 11 0.450
³2 1 1
central 0–1 33 9 0.016
³2 0 3
Decorin
portal 0–1 28 6 0.003
³2 0 4
lobular 0–1 28 7 0.014
³2 0 3
central 0–1 28 7 0.054
³2 0 2
a-SMA – a-smooth muscle actin; PSGL-1 – P-selectin 
glycoprotein ligand-1. * Liver status was recorded as abnormal 
if there had been a re-LT, diagnosis of chronic rejection or if 
there were 1 or more of the following laboratory findings: total 
bilirubin level over 25 µmol/L, GT over 50 U/L, ALT over 60 
U/L, and TT value <70%. ** p-value for the significance of the 










portal 0–1 26 7 0.042
³2 2 4
lobular 0–1 28 7 0.004
³2 0 4
central 0–1 26 10 1.00
³2 2 1
PSGL-1
portal 0–1 23 7 0.586
³2 3 2
lobular 0–1 26 7 0.061
³2 0 2
central 0–1 26 8 0.257
³2 0 1
CD34
portal 0–1 32 12 1.00
³2 1 0
central 0–1 32 12 1.00
³2 1 0
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found a relationship between portal inflammation and CD34-
positive sinusoids around central areas, which may reflect the 
role of CD34 in leukocyte infiltration [21].
The strength of our study is the simultaneous analysis of several 
biomarkers in liver grafts, the use of biopsies at baseline and a 
decade later, and the overall follow-up of the patients for more 
than 20 years after LT. The few previous studies of biomarker 
expression after LT (a-SMA, vimentin) did not evaluate their 
expression at the time of the transplantation and the follow-
up times were significantly shorter than in the present study.
Limitations of the present study include the small cohort size, 
which is common in pediatric transplant studies. The differenc-
es in number of patients and biopsies at different time-points 
is another limitation. Not all patients had biopsy samples at 
the 3 time-points examined. Baseline and second follow-up bi-
opsies were available from less than half of the patients. Also, 
unfortunately, for some stains, the level of missing data was 
high due to the insufficient size of biopsy samples. The retro-
spective nature of this cohort study and the time span of over 
20 years also brings limitations, although all patients visited 
the study center regularly. The semiquantitative scoring of the 
biomarker expression used in this study predisposes to sub-
jectivity, but unlike computer-assisted area fraction measure-
ments, it offers better accuracy for detecting false staining re-
sults and to study the expression of specific areas separately. 
The chosen biomarkers represent different aspects of pathol-
ogy (fibrosis, active inflammation, endothelial injury, and mes-
enchymal-to-epithelial transition), which is a strength but may 
also interfere with the results, as the main pathology of inter-
est was fibrotic development.
Our study results suggest that the use of immunohistochem-
ical stainings in LT patients can aid in the detection of fibrot-
ic changes. Controlled prospective trials are needed to further 
evaluate the value of immunostainings in liver graft follow-
up. We found that biomarker stainings clearly visualized the 
pathological liver graft lesions, especially fibrosis. However, 
conventional Masson’s trichrome staining was also sensitive 
in revealing fibrosis, and the immunostainings gave very little 
additional information. As the pathophysiology of the chron-
ic subclinical fibrosis and inflammation in liver grafts is not 
known, investigations focused on profibrotic and proinflam-
matory molecules are needed. Evaluation of vimentin levels 
in chronic (antibody-mediated) rejection is also warranted.
Conclusions
Our study shows that the expression of alfa-SMA, type I colla-
gen, decorin, and vimentin is increased in fibrotic liver grafts 
after LT. The portal expression a-SMA, decorin, and vimentin 
can reveal fibrotic changes in advance, even years after LT. 
However, the analysis of these 6 biomarkers in perioperative 
biopsies did not predict the later graft fibrosis.
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